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Abstract 
 
Background: 
  
Over the last thirty years, the management of Malignant Ureteric Obstruction 
(MUO) has evolved from a single disciplinary decision to a multi-disciplinary 
approach. Careful consideration must be given to the risks and benefits of 
decompression of hydronephrosis for an individual patient. Though there is 
some recommendations within cancer specific guidelines, both the European 
Association of Urology and the American Urological Association guidelines 
recommend drainage or de-obstructing the urinary systems. there is a lack of 
consensus of opinion as well as strong evidence to support the decision 
process. 
  
Methodology: 
  
The review was conducted using Cochrane and PRISMA guidelines. 
Outcomes that were identified amongst patients undergoing treatment for 
MUO included prognosis, quality of life (QOL), complications, morbidity and 
prognostication tools. 
  
  
Results: 
A total of 57 papers were included. Median survival was 6.8 months in the 50 
papers that stated this outcome. The average reported complication rate was 
41% with one fifth of patients never leaving hospital post procedure. 
Significant predictors to poor outcomes included low serum albumin, 
hyponatremia, the number of malignancy related events, and performance 
status of 2 or worse on the European cooperative cancer group. For those 
patients with 2 or more risk factors, median survival ranged from 1.7–2.6 
months and 12-month survival ranged from 0%-12%. QOL using several 
measures ranged from 41–88%. 
Conclusion: 
In this post Montgomery era with the concept of the ‘reasonable patient’, can 
we continue to justify discussing decompression without stating the evidence-
based risks from the emergent body of literature? We propose a multi-centre 
review of outcomes to enable evidence-based consultations for patients and 
their families. 
 
Introduction 
 
Malignant ureteric obstruction (MUO) is a condition that affects patients with 
advanced stages of cancer. It can be attributed to urological and non-
urological malignancies (gynecological, colorectal, haematological and 
retroperitoneal). An obstructed single system can significantly reduce patients’ 
quality of life of patients especially if infection ensues, however, bilateral 
obstruction will lead to a certain death. In fact upper urinary tract obstruction is 
a prognostic indicator of morbidity for many cancers (1–3).  
 
MUO management is usually a straightforward decision, with relief of 
obstruction causing significant improvements in the infected urinary tract, 
relief of pain and/or renal failure. However, the procedure and the 
nephrostomy tubes left in situ are not without complications, and therefore, 
the decision is more difficult to take in the palliative setting, as it can leave the 
patient burdened with more symptoms and complications with the often short 
time they have left.  
 
With a life-threatening obstruction the decision to decompress should be 
weighed against the prognosis of the patient’s condition, in addition to taking 
into account associated patient comorbidities, the need for further regular 
interventions, reduced quality of life from the nephrostomy or stent, and most 
importantly the patient’s preferences.  
 
Over the last thirty years, the management has evolved from a single 
disciplinary decision to a multi-disciplinary approach involving Urologists, 
Oncologists, Palliative care physicians, General Medicine physicians and 
Interventional Radiologists. This is mainly due to the fact that advanced 
stages of cancer is now treated with this multi-disciplinary approach, in 
addition the surgical approach to MUO has evolved from predominantly highly 
morbid open surgical procedures(4) to minimally invasive techniques (5). Brin 
et al. in 1975 described their ‘disappointing’ experiences of open palliative 
procedures with patients suffering ‘an inexorable downhill course’(6). 
Interestingly, oncologists are more likely to push for decompression in 
asymptomatic patients with a poor prognosis than urologists (7). 
Nevertheless, early support and advice from palliative and general medical 
physicians can significantly help alleviate suffering whichever decision is 
made. 
 
Individualized consideration must be given to the risks and benefits of 
decompression (6,8–12). Though there are recommendations within cancer 
specific guidelines, both the European Association of Urology (EAU) and the 
American Urological Association (AUA) guidelines recommend 
decompressing the urinary systems (16,17, 18, 19), there is a lack of 
consensus of opinion as well as strong evidence to support the decision 
process (2,4, 16, 17). The National institute for health care excellence (NICE) 
guidelines concluded that patients should be offered decompression, but that 
the option of ‘no intervention should also be discussed.’ They noted that there 
was insufficient low grade evidence in this arena (16, 17).  None of these 
recommendations take into consideration the implications of quality of life.  
 
To this end, we aimed to conduct a review of the literature to be able to inform 
the decision making process of managing patients with MUO. Specifically, we 
aim to distill the relevant evidence in this paper to help facilitate an evidence-
based consultation with patients and their families on prognostic outcomes of 
decompression in the setting of malignant ureteric obstruction (15). 
 
Methods 
 
Search strategy: 
The review was conducted using Cochrane and PRISMA guidelines (16–18). 
The search strategy included the following databases: The US National 
Library of Medicine’s life science database (MEDLINE) (1975- September 
2017), EMBASE (1975- September 2017), Cochrane Central Register of 
Controlled Trials - CENTRAL (in The Cochrane Library - 2017), CINAHL 
(1975- September 2017), Clinicaltrials.gov, Google Scholar and Individual 
urological journals. 
 
Search terms used included: “malignant ureteric obstruction”, “percutaneous 
nephrostomy”, “stent”, “quality of life” and “prognosis”.  
Medical Subject Headings (MeSH) phrases included:  
 
- (("Stents"[Mesh]) AND "Neoplasms"[Mesh]) AND "Quality of 
Life"[Mesh] 
- ((("Stents"[Mesh]) AND "Ureter"[Mesh]) AND "Neoplasms"[Mesh]) AND 
"Quality of Life"[Mesh] 
- ((("Stents"[Mesh]) AND "Ureteral Obstruction"[Mesh]) AND 
"Neoplasms"[Mesh]) AND "Quality of Life"[Mesh] 
- ((("Stents"[Mesh]) AND "Ureteral Obstruction"[Mesh]) AND 
"Neoplasms"[Mesh]) AND "Prognosis"[Mesh] 
- (("Nephrostomy, Percutaneous"[Mesh]) AND "Neoplasms"[Mesh]) AND 
"Quality of Life"[Mesh] 
- ((("Nephrostomy, Percutaneous"[Mesh]) AND "Ureteral 
Obstruction"[Mesh]) AND "Neoplasms"[Mesh]) AND "Prognosis"[Mesh] 
- ((("Nephrostomy, Percutaneous"[Mesh]) AND "Ureteral 
Obstruction"[Mesh]) AND "Neoplasms"[Mesh]) AND "Quality of 
Life"[Mesh] 
 
Study selection: 
 
Three authors (JP, TA, and OA) independently completed the review of 
literature independently and followed predefined inclusion criteria. 
Disagreement between the authors in study inclusion was resolved by 
consensus. 
 
Inclusion criteria 
 
All types of publications were included. Manuscripts involving adult patients 
(18 years old and above) with malignant ureteric obstruction in the English 
language were included. If only abstracts were available, these were included 
if sufficient data were extractable.  We included papers reporting on benign 
disease if the data could be extracted separately. 
 
Our outcome measures were: 
 
1) Prognosis in patients diagnosed with malignant ureteric obstruction 
(across all tumour groups) who received decompression via PCN or 
ureteric stenting 
2) Quality of life associated with the above 
3) Major and minor complications  
4) Morbidity defined as hospitalisation post-intervention 
5) Effect of decompression on renal function 
6) Prognostication tools in use to predict poor outcomes from intervention 
Data Extraction 
 
Data of each included study was independently extracted initially by 2 authors 
(JP and TA) after which a senior author (OA) extracted the data independently 
and cross checked each data extraction to ensure quality assurance of data. 
 
The following variables were extracted from each study:  Number of patients, 
gender, intervention, age, primary diagnosis, median survival, complications, 
amount of time spent in hospital, proportion of lifetime spent in hospital, 
proportion of patients not discharged, mortality, prognostication (where 
available) and quality of life. 
 
Where applicable the data of each study was pooled into a meta-analysis, in 
an intention to treat basis, to give a numerical representation of the results 
 
 
Results 
 
The initial review yielded 169 papers. Of these 70 were excluded after 
abstract screening, 35 were later excluded after full manuscript review. Of the 
thirty-five papers excluded.  Thirteen papers included benign causes, nine 
had no survival data, four used surgical diversion techniques and one paper 
excluded patients with poor outlook. Four were not available in the English 
language. Three authors were contacted to obtain manuscripts but did not 
respond.  In total, 57 papers were included in the review.  
 
 
Characteristics of included studies 
 
 
Seventeen studies were from United States of America, 12 from the United 
Kingdom, 6 from Japan, 4 from Brazil, 2 from Greece, 2 from Germany and 2 
from Korea. There was one paper authored from; Serbia, the Philippines, 
Singapore, China, Pakistan, Jordan, Turkey, Israel, Sweden, New Zealand, 
Australia and Austria.  
 
Only 9 studies were prospective in nature; of these one was a Prospective 
cohort study. There were no randomised controlled trials. The follow up period 
ranged from 6 months to 8 years.  
 
 
 
 
Demographics 
 
In total, 4948 patients were included in this study (1,3,8–11,15,19–43,43–62). 
Of which, 1030 patients had stents and 3891 had nephrostomies. Most 
papers classified patients by individual tumour type (table 1) (1,3,8–11,15,19–
43,43–63). The mean age of patients was 60 (range 19 – 97 years) (1,3,8–
11,15,19–25,27,28,31,32,34–38,40–42,44,47–49,51–53,55–57,59,60,62,63). 
 
Table 1: Distribution of cancers  
 
 
 
 
 
 
Type of cancer No of Patients 
included 
Prostate 1561 
Bladder 533 
Colorectal 473 
Gastrointestinal 300 
Cervical 829 
Uterine 64 
Other 605 
 
 
Prognosis 
 
Fifty papers included prognosis as an outcome measure with a total of 2790 
patients included. This ranged from 21 hours to 140 months with a median 
survival of 6.4 months (1,3,8–11,15,19–43,43–52,54,56–59,61–63).  
Eight papers provided a mean one year survival; the aggregate mean of the 
percentage of patients surviving one year was 23% 
(3,9,10,23,24,28,32,38,44). 
 
 
 
 
Quality of life 
 
Twenty papers assessed quality of life with a total of 824 patients 
(9,11,12,19–22,24,27,30,32,44,45,48,49,60,61,64–66). Measures included 
time spent in hospital, pain assessment and qualitative interviews.  
 
Five studies used the Grabstald outcome measure tool (167 patients), 
(19,20,49,61,65,67). A cumulative analysis of which, found that 60% of 
patients were able to achieve a ‘useful life’ post decompression. (table 2) 
 
Table 2: Papers using Grabstald ‘useful life measure’ 
Paper Type Date Number 
and 
male/fem
ale 
average 
age 
Tumour 
type 
Stent/neph
rostomy 
(n patients) 
Gradstal
d 
percent
age 
Hubner et al 
.1993 
Retrosp
ective 
1986-
1989 
52 
(31 f, 21 
m) 67 
(43-81) 
Prostate 
7% 
Bladder 
25% 
Colorectal 
28% 
Cervix 
17% 
Ovarian 
11% 
Other 2% 
Stent 24, 
PCN 28 
81% 
Hoe et al. 
1993 
Retrosp
ective 
Not 
stated 
Not 
stated 
Colorectal 
33% 
Cervix 5% 
Prostate 
PCN 24 46 % 
  
Two studies used the functional assessment of cancer therapy (FACT) 
concerning nephrostomy insertion or not and nephrostomy versus stent 
insertion. Neither had significant difference between the groups. One study 
used the European Organization for Research and Treatment of Cancer 
Quality of life questionnaire (EORTC- QOLC –C30)(60). There was no 
significant difference in quality of life when administered pre and post 
nephrostomy insertion (table 3) Aravantinos et al. used the European 
Organisation for Research and Treatment of Cancer Quality of life 
questionnaire (EORTC- QOLC –C30)(60). There was no significant difference 
in quality of life when administered pre and post nephrostomy insertion.  
 
 
Table 3: Quality of life  
 
5% 
Bladder 
5% 
Rest not 
stated. 
 
 
Emmert et 
al. 1997 
 
Retrosp
ective 
 
1990-
1995 
 
24 
Age 45.9 
(30-79) 
 
Cervical 
100% 
 
 
PCN 24 
 
 
46 % 
Feng et al. 
1999 
Retrosp
ective 
1984-
1996 
37 
(20 f, 17 
M) 37-85 
no mean 
Prostate 
27% 
Bladder 
13% 
Colorectal 
10% 
Cervix 
32% 
Uterus 5% 
Ovarian 
10% 
Stent 22, 
PCN 15 
82-87% 
classifie
d into 
two 
groups 
Wilson et al. 
2005 
Retrosp
ective 
1996- 
2001 
32 
(16 male 
and 16 
female) 
age 68.1 
(42-84) 
Prostate 
28% 
Bladder 
25% 
Colorectal 
21% 
Cervix 
15% 
Uterus 6% 
Breast 3% 
PCN 32 46.9% 
 Author Patient 
details 
Assessment Outcome 
Aravantinos 
et al. 2007 
207 
Bladder, 
Prostate, 
Cervical, 
Gynaecologic
al 
EORTC- 
QOLC –C30 
No significant difference in 
quality of life when 
administered pre and post 
nephrostomy insertion. 
Monsky et al. 
2013 
 
46 (13 lost to 
follow up) 
Bladder 14, 
cervical 15, 
Prostate 6, 
Uterine 5, 
Other 7 
PCN = 15 
Stent = 31 
 
FACT-BL No statistical differences in 
patients’ responses post 
stenting or PCN insertion. 
Patients with stents reported 
significantly greater pain and 
storage lower urinary tract 
symptoms, although this did 
not translate into a reduction 
in measured quality of life 
(QOL). 
Lapitan et al. 
2011 
Cervical 
cancer 
FACT-G There was no statistical 
difference in the FACT-G 
scores for patients with or 
without PCN 
Bigum et al. 
2015 
10 (Prostate 
8, Bladder 
cancer 2) 
All 
Nephrostomy 
Qualitative 
interview 
 
Main themes: 
Lack of follow up, 
complications, physical 
limitations and the impact on 
their social life 
Kumar et al. 
2015 
17 patients 
All PCN 
Ovary 6, 
Uterine 3, 
Cervical 2 
Qualitative 
interview 
 
 
Main themes: 
Symptoms from 
decompression, an 
educational void and the role 
of self education 
(30% no symptoms 
 
 
 
Complications 
 
Twenty-four of the papers commented on the frequency of complications with 
a total of 1891 patients. The overall complication rate was 41% 
(10,11,15,21,22,25,31,32,35,38,44,50,58). 
 
 
Minor complication 
 
26% (439/1658) of patients with nephrostomies developed urinary infection 
whilst 14% (26/180) of patients with stents placed developed infections. 10% 
(173/1658) patients experiencing dislodged nephrostomies whilst 7% 
(113/1658) of patients developed blocked nephrostomies. Stent 
migration/dislodgement was reported in 6% (10/180).  
 
Major complications 
 
Haematuria rate 8% (15/180) in patient’s stented compared to 3% (49/1658) 
in patients with nephrostomies. Nephrectomy rate was 0.2% (4/1658) 
following PCN placement; 2 for perinephric abscess (the indication for the 
other two patients was not stated) (31,32).  Mortality rate was 0.2% (4/1658); 
three from haemorrhage and one from sepsis. In the three papers who 
reported mortality the overall rate was 5% (4/82) (21,51,61). 
  
 
 
Disease Mortality 
 
 
Twelve papers (628 patients) calculated the proportion of patients who never 
left hospital post decompression (9,11,20–22,27,30,32,44,54,61,63) with the 
pooled mean for this being 26% (5-69%).  
 
Patients spent 20% of their remaining lifetime in hospital 
(8,22,27,32,36,43,44,47,48,52,61,63).  
 
 
Renal function 
 
 
Twelve papers included renal function pre and post procedure (a total of 1135 
patients). Pre nephrostomy, the average creatinine was 624 mmol/L and post 
procedure, the creatinine improved to 212 mmol/L on average 
(9,10,20,22,30,42,43,48,53,59,60,68).  
 
 
Prognostication tools 
 
Sixteen papers with a total of 2061 patients investigated various factors and 
their ability to prognosticate (3,9,10,23,24,27,29,30,35,37,41,53,60,69–71) in 
these patients.  
 
 
These were found to include low serum albumin (10,29,35,41,71), no further 
treatment options(3,23,37,53),  hyponatraemia (29,35), number of malignancy 
related events (pleural effusion, metastatic disease, ascites) (10,29,35,41), 
the  presence of metastatic disease (27,60), performance status of 2 or worse 
on the European cooperative cancer group (ECOG) (9,23,53,71).  
 
Patients with a malignancy of unknown primary or gastrointestinal origin were 
identified as having poorer outcomes (27,41) whereas gynaecological 
malignancies had a better outcome(37). Other variables included patients with 
upper ureteric obstruction (23), moderate-severe hydronephrosis (24),  
bilateral hydronephrosis (41), elevated creatinine (24,37), anaemia (55) and 
patients with an elevated CRP(29)  
 
 
Table 4: Summary of literature on Prognostication 
Paper Study 
type 
N Age 
(rang
e) 
Process Tumour type 
(%) 
Features of 
poor outcome 
(statistically 
significant) 
Survival based on 
predictors 
Feuer 
et al.  
1991 
Prospec
tive 
22 58 
(n/a) 
Univarat
e, 
Kaplain 
Meyer 
Cervical 77 
Gynaecologic
al (other) 18 
Uterine 4 
Patients having 
one of: 
progressive 
tumour, 
Performance 
status >2, 
tumour related 
medical 
problems, no 
treatment, 
uncontrolled 
pain 
Survival  
242 days (if 0 factors) 
vs 37 days (if 1 or 
more factor) 
Days at home 
164 days (if 0 factors) 
vs 37 days (if 1 or 
more factor) 
 
 
Watkins
on et al. 
1993 
Retrosp
ective 
Case 
series 
50 53 Groupin
g – no 
statistica
l 
analysis 
Cervical 32 
Bladder 36, 
Colon 10 
Lymphoma 4,  
Ovary 4 
Other 6 
 
Not identified 12 month survival 
Group I - benign or 
treated (100%) 
Group II untreated 
malignancy (50%)  
Median survival 339 
days 
Group III ureteric 
obstruction by 
abdominopelvic 
disease with treatment  
(50%)  
Median survival 334 
days 
Group IV ureteric 
obstruction by 
abdominopelvic 
disease without 
treatment (0%) 
Median survival 38 
days 
 
Wong 
et al. 
2007 
Retrosp
ective 
case 
series 
10
2 
62  
(31-
86) 
Univariat
e and 
multivari
ate 
Gastric 20 
Gynaecologic
al 31  
Urological 29 
Presence of 
metastatic 
disease 
Diagnosis of 
12 month survival 
63% in favourable (0-1 
unfavourable factors) 
 12% in unfavourable 
analysis 
Kaplain 
Meyer 
Other 18 MUO in 
presence 
established 
malignancy 
(4 unfavourable 
factors) 
 
Jeong 
et al. 
2007 
Retrosp
ective 
case 
series 
86 54  
(23-
79) 
Univariat
e and 
multivari
ate 
analysis  
Gastric 33, 
Cervical 10 
Colorectal 40, 
Prostate 0, 
Bladder 0, 
Other 17 
 
 
ECOG 2 or 
more 
Lesion in upper 
ureter 
No treatment 
options post 
nephrostomy 
No prognostication tool 
suggested 
Aravanti
nos et 
al.  
2007 
Retrosp
ective 
50
7 
63 
(40-
85) 
Kaplan-
Meyer 
curves 
and 
Mann 
Whitney 
for QOL 
 
Bladder 32  
Prostate 26  
Colorectal 17  
Gynaecologic
al 13  
Other 8 
gastric/pancr
eatic 3 
 
Disseminated 
disease 
(significant for 
Prostate and 
Colorectal 
cancer only) 
All patients 6 month 
survival 
33% survival > 6 
months 
 
 
 
 
 
 
Ishioka 
et al. 
2008 
Prospec
tive 
14
0 
57  
(31-
85) 
Multivari
ate 
analysis 
Kaplain 
Meyer 
Gastric 21, 
Cervical 21 
Urothelial 9, 
Colorectal 24, 
Other 10 
3 or more 
cancer related 
events 
Low serum 
albumin 
Low grade 
hydronephrosis 
 
6 month survival  
69% in favourable 
group (0 risk factors) 
Intermediate group 
24% (1 risk factor)  
Poor group 2% (2-3 
risk factors) 
Lienert 
et al. 
2009 
Retrosp
ective 
49 71  
(36-
91) 
Univariat
e 
Cervical 6 
Colorectal 12 
Bladder 36, 
Prostate 30  
Other 14 
Three or more 
cancer related 
events 
Low serum 
albumin 
Low serum 
sodium  
 
Mean survival in 
months 
9 months for 0 risk 
factors 
5.7 months for1 risk 
factor  
2 months for 2 or 3 risk 
factors 
Jalbani 
et al. 
2010 
Prospec
tive 
40 No 
avera
ge 
(21-
70) 
Paired T  Cervical 37 
Rectum 7 
Bladder 25, 
prostate 12 
Rectum 7 
None identified Good prognostic 
features 
Recent diagnosis 
 Age <52  
Izumi et 
al. 2011 
Retrosp
ective 
61 64  
(27-
89) 
Univariat
e and 
multivari
ate 
analysis  
Gastric 24  
Cervical 26 
Colorectal 12 
ovarian 9 
Bladder 3 
Prostate 5 
High creatinine 
(>106micromol/
L) 
No treatment 
options 
Non 
gynaecological 
Survival in months  
Good predictors 13.2 
months 
Intermediate 8.2 
months  
Poor 1.7 months 
cancer 
Migita 
et al. 
2011 
Retrosp
ective 
25 61 Multivari
ate 
analysis 
Kaplain 
Meyer 
Gastric 100 No treatment 
options 
 
Survival  
3.1 Months if no 
treatment options 
11.2 months if 
treatment options 
 
Azuma 
et al. 
2013 
Retrosp
ective 
21
4 
79% 
<80 
21% 
>80 
Multivari
ate 
Gastric 16 
Cervical 15 
Colorectal 21 
Urothelial 15 
Prostate 14 
Other 28 
 
Number event 
related to 
malignant 
dissemination 
Low serum 
albumin 
Low serum 
sodium  
High CRP  
 
Median survival  
12 months Favourable 
(0-1 risk factors) 6 
months Intermediate (2 
risk factors) 2.6 
months Poor group (3 
risk factors) 
 
 
Souza 
et al. 
2016 
Retrosp
ective 
48 59  
(6-
85) 
Univariat
e 
Multivari
ate 
analysis  
Cervical 100 Haemaglobin 
<8.7g/dL 
Haematocrit 
<27% 
Hypotension (in 
absence of 
sepsis) 
Not calculated 
Compared 
characteristics of 
group that died 
compared with survival 
group 
Alawne
h et al.. 
2016 
Retrosp
ective 
21
1 
59  
(6-
85) 
Multivari
ate 
analysis 
Kaplain 
Meyer 
Gastrointestin
al 28 
Genitourinary 
58 
Other 13 
Presence of 
ascites, pleural 
effusion,  
Low serum 
albumin,  
Bilateral 
hydronephrosis 
Gastrointestinal 
malignancy  
 
12 month survival 
0 factors 78%, 1 factor 
36%  
2 factors 17%, 3 
factors 6%  
 
Cordeir
o et al. 
2016 
 
 
Prospec
tive 
20
8 
61 
(19-
89) 
Multivari
ate 
analysis 
Kaplain 
Meyer 
Cervical 20 
Colorectal 21 
Bladder 22 
Prostate 12 
Number 
malignant 
events > or 
equal to 4 
ECOG > or = 2 
12 month survival 
Favourable (0 factors) 
45%  
Intermediate (1 factor) 
15% Unfavourable (2 
factors) 7% 
Downey 
et al. 
2016 
(abstrac
t only) 
Retrosp
ective 
 
86 - Groupin
g – no 
statistica
l 
analysis 
Bladder 35 
No further 
data 
 
 Not identified 12 month survival  
(Based on Watkinson 
et al 1993) 
Group I (non 
malignant) no data 
Group II (untreated 
primary) 20%, 
Group III (relapsed 
 
 
 
 
 
 
 
 
 
disease viable option) 
16% 
Group IV (no treatment 
option) 0% 
 
 
Gandiy
a et al. 
2017 
(abstrac
t only) 
Retrosp
ective 
19
3 
70 
(26-
90) 
Multivari
ate 
analysis 
Kaplain 
Meyer 
Urological 47 
gynaecologic
al 22 
Colorectal 11, 
other 20 
 
Low serum 
albumin 
ECOG > or = 2 
Prior 
oncological 
treatment  
Pooled survival 
82% survival at 1 
month 
63% at 3 months 
50% survival at 6 
months 
Discussion 
 
This review of 57 papers gives a broad survival range for patients with 
malignant ureteric obstruction; between 21 hours and 140 months (1,3,8–
11,15,19–43,43–52,54,56–59,61–63). The median survival was 6.4 months 
and the percentage of patients alive at one year was 23% 
(3,9,10,23,24,28,32,38,44). Reasons for this variation in survival include the 
heterogeneous patient and cancer groups involved. Additionally, the data is 
limited by the fact that researchers in some instances may have included 
patients with retroperitoneal fibrosis secondary to treatment (such as 
radiotherapy) rather than ongoing or recurrent disease (72,73). The benign 
nature of this aetiology for obstruction would skew results towards improved 
outcomes. The majority of the papers reported on  patients whom underwent 
decompression; therefore not capturing a proportion of patients who were not 
decompressed.   
 
The proportion of patients whom had complications was 41% with 26% of 
patients never leaving hospital. Those who had an intervention spent 20% of 
their resultant lifetime in hospital. The placement of a stent or nephrostomy is 
morbid. In addition to this there is no improvement of quality of life; an often 
stated claim of decompression.  
 
One paper stated that 69% of their patients never left hospital. Removing this 
apparent outlier from the pooled mean resulted in the figure of 17.8% (21).   
Despite improving renal function creatinine did not return to base line for 
patients; potentially avoiding an emergency situation but not reversing the 
damage caused by hydronephrosis. 
 
 
Two pertinent questions are always presented: what are the preferred options 
for relieving malignant ureteric obstruction? And; what is the expected 
prognosis (5)? In terms of methods of decompression; a previous comparative 
study discovered no relative superiority of retrograde stenting to percutaneous 
nephrostomy (PCN) in the setting of infected obstructed uropathy caused by 
stones (74). There are various options for managing malignant ureteric 
obstruction based on patient and oncological factors as well as clinical factors. 
This includes the specialty of the coordinating team and institutional factors 
such as the availability of interventional radiologists (7). Two recent review 
articles concluded that there was no data on the superiority of stent versus 
percutaneous nephrostomy +/- subsequent antegrade stent when considering 
malignant and benign ureteric obstruction (5,75).  Cordeiro et al., Lang et al. 
and Wong et al. divided complications by intervention type, with 38%, 64% 
and 53% of patients respectively reporting complications with nephrostomies 
(9,27,58). The rate of complications for stents was 56% in Wong et al., 48% in 
Lang et al. series and 42% in the Cordeiro et al series(9,27). Wong however 
found that there was no statistically significant difference in the rate of 
complications between stents and nephrostomies (9,27,58).  
 
 
Clearly, the aim of relieving the obstruction depends on patient factors but 
would include improving renal function to enable further oncological treatment, 
to correct the symptoms of renal failure and to improve pain (7). This must be 
balanced against a patient’s expectation of quantity and quality of life. This is 
of course is a challenging consultation; particularly in the acute setting when 
such patients often present (69). Despite extensive retrospective publications 
and several review articles, there is a paucity of data assessing the important 
issues of quality of life and prognostication in this cohort of patients. (5). 
Historically, with regards to malignant ureteric obstruction; researchers 
equated quality of life with quantity of life the use of opioids (48) and time 
spent out of hospital (20,22,47). More recently, patient interviews and patient 
reported outcome measures (PROMs) have been developed to evaluate the 
impact of interventions on patients from their personal viewpoints 
(12,24,64,76).  
 
European Association of Urology (EAU) guidelines on pain management 
recommend that for pelvic malignancies ‘it is good practice to drain 
symptomatic hydronephrosis at once, and to drain only one kidney (the less 
dilated and better appearing kidney or the one with the better function, if 
known) in asymptomatic patients (77). They conclude that a nephrostomy 
tube is superior to a double-J stent for drainage for pelvic malignancies but 
advocate either stenting or nephrostomies in other tumour groups (77). 
Neither of these recommendations references the literature nor do they 
mention implications of quality of life.  
In the context of locally advanced non metastatic bladder cancer with 
hydronephrosis, American Urological Association (AUA) guidelines suggest 
placement of a ureteral stent (78). 
 
 
Complications 
 
Another frequently neglected statistic for patients prior to them undergoing 
decompression is the proportion of time spent in hospital and the risk of 
complications. The proportion of patients whom had complications was 41% 
with 26% of patients never leaving hospital. Those who had an intervention 
spent 20% of their resultant lifetime in hospital. One paper stated that 69% of 
their patients never left hospital. Removing this apparent outlier from the 
pooled mean resulted in the figure of 17.8% (21).   Despite improving renal 
function creatinine did not return to base line for patients; potentially avoiding 
an emergency situation but not reversing the damage caused by 
hydronephrosis. 
 
 
Quality of life  
 
Quality of life can be challenging to measure; early papers measured QOL 
using the ‘useful life’ measure (49,65). Feng et al. and Hubner et al. reported 
greater proportions of patients achieving a good QOL when compared with 
contemporary papers; 81-87% versus 46% (19,20,49,61,65). Whilst it is not 
entirely clear why there has been a reduction in patients experiencing ‘useful 
life’; it is possible that this may relate to patient selection, subjective clinician 
perception of pain and possibly the increased use of opioid medication (79). 
Furthermore it is likely that the progression to use of PROMs rather than 
relying on clinicians’ opinions of what constitutes quality of life can explain in 
part the move from rudimentary to more patient-centered validated measures.  
 
Three studies utilised PROMs demonstrating no statistically significant 
improvements in quality of life pre and post decompression (24,60,64). 
However, despite improvement in the use of PROMs there were several 
limitations with the studies. Limitations of the Monskey et al. study included 
not measuring baseline symptoms and not having a control group (64). 
Lapitan and colleagues, despite conducting a prospective study using FACT–
BL, demonstrated lower scores pre and post decompression in comparison to 
other papers using FACT-G (24). This is potentially related to the association 
between socioeconomic deprivation, educational attainment and scores in 
FACT-G (80,81).  A further limitation of the Lapitan et al. study reducing its 
wider relevance was the inclusion of patients solely with a diagnosis of 
cervical cancer.  
 
Two papers looked at qualitative interviews. Qualitative analysis is helpful to 
develop themes. However a small sample size, the challenges of 
confounders, single tumour group inclusion and the exclusion of patients 
without nephrostomies may limit its wider application (12,66). 
 
Prognostication 
 
One group performed a prospective cohort study of patients with cervical 
cancer. Lapitan et al. followed up a cohort of patients who had malignant 
ureteric obstruction and assessed the outcomes of two groups; those who 
were decompressed and those who were not (24). At the outset, there 
appears to be a survival benefit with 38% versus 28% survival at six months 
for those who underwent decompression versus those who did not. By 12 
months however, both groups had the same survival of 16% (24). 
 
 
The most frequently found statistically significant indicators of poor prognosis 
were  
low serum albumin (10,29,35,41,71), no further treatment options(3,23,37,53), 
number of malignancy related events (pleural effusion, metastatic disease, 
ascites) (10,29,35,41), performance status of 2 or worse on the European 
cooperative cancer group (ECOG) (9,23,53,71), the presence of metastatic 
disease (27,60), and hyponatremia (29,35). Two papers divided patients into 
groups depending on treatment options available; those with no treatment 
options had 0% 12 month survival and a median survival of 38 days (69,70). 
Combining these parameters with a larger patient group may help develop a 
prognostication tool for clinicians to aid decision-making.  
 
The authors have assessed the pertinent features of poor prognosis in 
malignant ureteric obstruction as highlighted in this review. We feel the tool 
below may have some clinical utility in counseling patients for decompression 
or otherwise. As readers are no doubt aware, it is not unusual for these 
patients to present emergently and often unwell. A simple adjunct to clinical 
practice could have a role in alerting clinicians to pertinent parameters to 
consider: 
 
Table 5 Proposed prognostication Tool (PALLIATE) 
 
 
 
 
 
 
 
 
 
 
 
 
Comparison of prognostication tools demonstrates patients with none or 1 risk 
factor have a more favourable outcomes with 12 month survival ranging from 
20% to 78%(27,41,69,70) and a median survival ranging between 9 and 13 
months (29,35,37). In those patients with ‘intermediate’ risk factors (see table 
4), median survival ranged from 5.7 to 8.2 months (29,35,37). For those 
patients with 2 or more risk factors, median survival ranged from 1.7 – 2.6 
months(29,37) and 12 month survival ranged from 0% to 12% (9,27,41,69,70) 
 
Cordeiro et al., Lang et al. and Wong et al. divided complications by 
intervention type, with 38%, 64% and 53% of patients respectively reporting 
complications with nephrostomies (9,27,58). The rate of complications for 
stents was 56% in Wong et al., 48% in Lang et al. series and 42% in the 
Cordeiro et al series(9,27). Wong however found that there was no 
statistically significant difference in the rate of complications between stents 
and nephrostomies (9,27,58).  
 
 
 
Limitations 
 
The reviewed data has significant heterogeneity making conclusions 
regarding specific tumour types challenging. Soulitududes et al. comments on 
the ‘divergent nature of their group’. At one end of the spectrum, there are 
patients with very advanced disease who may not benefit from 
decompression, at the other are those who have further oncological and or 
surgical options who will naturally have a much longer life expectancy(5).  
 
There are only nine papers including patients from the last ten years; in this 
time however there have been significant advances in oncological treatment 
options (9,10,15,29,35,41,55–57,59). Therefore, outcomes may well be 
influenced by more conservative historic data.  
 
Performance status (ECOG2) 
Albumin (low) 
Low serum sodium 
Laterality 
Inflammatory markers (CRP) 
Ascites 
Tumour type 
Events related to cancer (pleural effusions, metastatic disease) 
Another limitation of this analysis is the retrospective nature of the data; there 
were only seven papers that were prospective in nature 
(9,10,24,30,42,47,53). Data on survival is lacking on those patients 
conservatively managed with only one paper including untreated patients in its 
survival data which may lead to overstating median survival (24). There are 
clear worldwide variations in practice regarding discharge home. In one 
series, 69% of patients did not leave hospital after decompression (27); this 
contrasts with an average of 17% amongst other papers.  
 
Limitations when reviewing prognostic tools include the fact that the majority 
of studies were retrospective in nature. The use of statistical analyses 
included univariate, paired-T as well as multivariate analysis thus limiting 
transferability and utility on an individual patient basis.  
 
Conclusion 
 
In this post Montgomery era with the concept of the ‘reasonable patient’, can 
we continue to justify discussing decompression without stating to patients the 
evidence-based risks and benefits from the emergent body of literature? (82) 
An overall complication risk of 41% and up to one third of patient remaining 
lifetime spent in hospital with a median survival of 6.4 months may encourage 
clinicians and patients to rethink the appropriateness of such interventions.  
 
 
Implications of research 
 
We propose a contemporary multi-centre prospective review of outcomes of 
this cohort of patients to enable evidence-based consultations for patients and 
their families. Further work in the domain of prognostication is needed to help 
best identify those patients who may benefit the most from decompression.  
 
 
Implications of clinical practice 
 
Consideration of the median survival in patients undergoing PCN and 
nephrostomies; no increase in quality of life and a complication rate of 41% 
should be made when deciding with patients whether they are likely to benefit 
from decompression. The decision to decompress a patient should be an 
MDT based decision integrating prognostication based research sumarised 
here. This should include information on disease status, performance status 
and treatment options.   
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